Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7406702 | 0.85 | SIGMAR1 (0.50) | SIGMAR1CES1MPOSRD5A1SRD5A2 | |
| SCHEMBL28424372 | 0.80 | SIGMAR1 (0.46) | SIGMAR1CES1MPOSRD5A1SRD5A2 | |
| SCHEMBL6825529 | 0.80 | SIGMAR1 (0.46) | SIGMAR1CES1MPOSRD5A1SRD5A2 | |
| SCHEMBL11503302 | 0.80 | MPO (0.57) | SIGMAR1CES1MPOHPGDL3MBTL1 | |
| SCHEMBL9379776 | 0.80 | SIGMAR1 (0.46) | SIGMAR1CES1MPOG6PC1CYP2A6 | |
| SCHEMBL7837577 | 0.80 | SIGMAR1 (0.46) | SIGMAR1CES1MPOSRD5A1SRD5A2 | |
| SCHEMBL29446311 | 0.80 | SIGMAR1 (0.46) | SIGMAR1CES1MPOG6PC1CYP2A6 | |
| SCHEMBL2674626 | 0.79 | SIGMAR1 (0.43) | SIGMAR1CES1SRD5A1SRD5A2HPGD | |
| SCHEMBL3614042 | 0.79 | HTR6 (0.53) | CES1HPGDL3MBTL1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL10649574 | 0.78 | SIGMAR1 (0.44) | SIGMAR1CES1MPOG6PC1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0394194-B1 | PROTECTED AMINO-ACIDS AND PROCESS FOR THEIR PREPARATION | CALBIOCHEM-NOVABIOCHEM AG (CH) | 1993-08-18 | — | — | EP | claimed |
| JP-10109965-A | — | — | None | — | — | JP | disclosed |
| US-20070161598-A1 | Compositions and methods for treatment of disease with acetylated disaccharides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-12 | — | — | US | disclosed |
| EP-0832883-B1 | Tetrahydrobenzo(a)fluorene compounds and methods of use | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| US-5821253-A | INHIBIT BONE LOSS OR RESORPTION, LOWER SERUM CHOLESTEROL LEVELS | ELI LILLY AND COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| JP-H10109965-A | TETRAHYDROBENZO(A)FLUORENE COMPOUND AND ITS USE | ELI LILLY & CO | 1998-04-28 | — | — | JP | disclosed |
| EP-0832883-A1 | Tetrahydrobenzo(a)fluorene compounds and methods of use | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0281283-B1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-10 | — | — | EP | disclosed |
| US-4910212-A | Containing 1,2,4-triazole or imidazole ring | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-20 | — | — | US | disclosed |
| EP-0281283-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161598-A1 | Compositions and methods for treatment of disease with acetylated disaccharides | ASAH2, ALG1, MAN2B1 | SIGMAR1 3917/4885CES1 234/4885MPO 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.